Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU)

Molecular Genetics and Metabolism

Volumn 101, Issue 2-3, 2010, Pages 110-114

  Burton, Barbara K ^a,b   Bausell, Heather ^b   Katz, Rachel ^b   LaDuca, Holly ^a   Sullivan, Christine ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c CHILDREN S MEMORIAL RESEARCH CENTER   (United States)

Author keywords

Blood; Phenylalanine; Phenylketonuria; Sapropterin

Indexed keywords

KUVAN; PHENYLALANINE; SAPROPTERIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COGNITION; DRUG EFFICACY; FEMALE; HUMAN; INTELLIGENCE QUOTIENT; MALE; PHENYLKETONURIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BIOPTERIN; CHILD; CHILD, PRESCHOOL; COGNITION; FEMALE; HUMANS; INFANT; MALE; PHENYLALANINE; PHENYLKETONURIAS; RETROSPECTIVE STUDIES;

EID: 77957233995     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.06.015     Document Type: Article

References (11)

1. Christ S.E., Huijbregts S.C., de Sonneville L.M., White D.A. Executive function in early-treated phenylketonuria: profile and underlying mechanisms. Mol. Genet. Metab. 2010, 99(Suppl 1):S22-S32.
2. Brumm V.L., Bilder D., Waisbren S.E. Psychiatric symptoms and disorders in phenylketonuria. Mol. Genet. Metab. 2010, 99(Suppl 1):S59-S63.
3. Waisbren S.E., Noel K., Fahrbach K., Cella C., Frame D., Dorenbaum A., Levy H. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol. Genet. Metab. 2007, 92:63-67.
4. Anastasoaie V., Kurzius L., Forbes P., Waisbren S. Stability of blood phenylalanine levels and IQ in children with phenylketonuria. Mol. Genet. Metab. 2008, 95:17-20.
5. Levy H.L., Milanowski A., Chakrapani A., Cleary M., Lee P., Trefz F.K., Whitley C.B., Feillet F., Feigenbaum A.S., Bebchuk J.D., Christ-Schmidt H., Dorenbaum A., Sapropterin Research Group Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomized placebo-controlled study. Lancet 2007, 370:504-510.
6. Lee P., Treacy E.P., Crombez E., Wasserstein M., Waber L., Wolff J., Wendel U., Dorenbaum A., Bebchuk J., Christ-Schmidt H., Seashore M., Giovannini M., Burton B.K., Morris A.A., Sapropterin Research Group Safety and efficacy of 22weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am. J. Med. Genet. A 2008, 146A:2851-2859.
7. Levy H., Burton B., Cederbaum S., Scriver C. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH4) in phenylketonuria and its use in treatment. Mol. Genet. Metab. 2007, 92:287-291.
8. Gersting S.W., Lagler F.B., Eichinger A., Kemter K.F., Danecka M.K., Messing D.D., Staudigl M., Domdey K.A., Zsifkovits C., Fingerhut R., Glossman H., Roscher A.A., Muntau A. Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo. Hum. Mol. Genet. 2010, 19:2039-2049.
9. Koch R., Azen C., Friedman E.G., Williamson M.L. Paired comparisons between early treated PKU children and their matched sibling controls on intelligence and school achievement test results at eight years of age. J. Inherit. Metab. Dis. 1984, 7:86-90.
10. Antshel K.M. ADHD, learning and academic performance in phenylketonuria. Mol. Genet. Metab. 2010, 99(Suppl 1):S52-S58.
11. Walter J.H., White F.J., Hall S.K., MacDonald A., Rylance G., Boneh A., Francis D.E., Shortland G.J., Schmidt M., Vail A. How practical are recommendations for dietary control in phenylketonuria?. Lancet 2002, 360(9326):55-57.